Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer After Failure of at Least Two Prior Lines of Standard Therapy: A Single-Center, Open-Label, Single-Arm, Phase II Exploratory Study (BECOME Trial)

NCT07884188 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07884188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07884188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer After Failure of at Least Two Prior Lines of Standard Therapy: A Single-Center, Open-Label, Single-Arm, Phase II Exploratory Study (BECOME Trial)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
October 15, 2026
Completion date
October 15, 2031
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer